References
- FaderlSTalpazMEstrovZO’BrienSKurzrockRKantarjianHMThe biology of chronic myeloid leukemiaN Engl J Med1999341316417210403855
- SawyersCLChronic myeloid leukemiaN Engl J Med1999340171330134010219069
- KantarjianHMTalpazMGilesFO’BrienSCortesJNew insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceAnn Intern Med20061451291392317179059
- JemalASiegelRWardECancer statistics, 2006CA Cancer J Clin200656210613016514137
- HuangXCortesJKantarjianHEstimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyCancer2012118123123312722294282
- SEER Cancer Statistics Review, 1975–2006, [webpage on the Internet]Bethesda, MDNational Cancer Institute2008 [cited 04/16/2012]. Available from: http://seer.cancer.gov/csr/1975_2006/Accessed 06/11/2013
- HughesTPHochhausABranfordSLong-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood2010116193758376520679528
- KlokeOOpalkaBNiederleNInterferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single centerLeukemia200014338939210720131
- BonifaziFde VivoARostiGChronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic respondersBlood200198103074308111698293
- O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
- BjörkholmMOhmLElorantaSSuccess story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008J Clin Oncol201129182514252021576640
- US Food and Drug AdministrationImatinib Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdfAccessed March 19, 2013
- US Food and Drug AdministrationFDA grants accelerated approval of a new dosing regimen of dasatinib (Sprycel) [press release]Silver Springm, MDUS Food and Drug Administration2007 [November 13]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129236.htmAccessed March 19, 2013
- US Food and Drug AdministrationNilotinib (Tasigna) Available at: [press release]Silver Spring, MDUS Food and Drug Administration2010 [June 18]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm216218.htmAccessed March 19, 2013
- US Food and Drug AdministrationPonatinib [press release]Silver Spring, MDUS Food and Drug Administration2012 [December 17]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm332368.htmAccessed March 23, 2013
- US Food and Drug AdministrationBosutinib tablets [press release]Silver Spring, MDUS Food and Drug Administration2012 [September 5]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htmAccessed March 17, 2013
- PuttiniMColucciaAMBoschelliFIn vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cellsCancer Res20066623113141132217114238
- Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
- AbbasRHugBALeisterCGaaloulMEChalonSSonnichsenDA phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjectsCancer Chemother Pharmacol201269122122721691746
- CortesJEKantarjianHMBrümmendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood2011118174567457621865346
- KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
- CortesJEKimDWKantarjianHMBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJ Clin Oncol201230283486349222949154
- Gambacorti-PasseriniCKhouryHJSafety and efficacy of BOS in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to IM and other TKIs: update from study SKI-200Presented at the American Society of Clinical OncologyJune 4–8, 2010Chicago, IL, USA Abstract 6509
- Gambacorti-PasseriniCBrummendorfTHCortesJEEvolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapyPresented at the American Society of Clinical OncologyMay 31–June 4, 2013Chicago, IL, USA
- KhouryHJCortesJEGambacorti-PasseriniCActivity of bosutinib by baseline and emergent mutation status in Philadelphia chromosome-positive leukemia patients with resistance or intolerance to other tyrosine kinase inhibitorsPresented at the Annual Meeting of the American Society of HematologyDecember 11, 2011San Diego, CA, USA
- RedaelliSMologniLRostagnoRThree novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitorsAm J Hematol201287E125E12823044928
- TraskPCCellaDBessonNKellyVMassziTKimDWHealth-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemiaLeuk Res201236443844222036634